The use of serological biomarkers represents an appealing approach to support hepatocellular carcinoma surveillance systems and early diagnosis which also benefits monitoring of hepatocellular carcinoma therapy.[15,16] The diagnosis and monitoring of hepatocellular carcinoma significantly depends on alpha-fetoprotein (AFP) because it stands as the leading biomarker among those currently known. This evidence concerns the gene AFP and hepatocellular carcinoma.